Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes investigation 2020-05, Vol.11 (3), p.748-749
Hauptverfasser:	Miyauchi, Masaaki, Toyoda, Masao, Zhang, Jie, Hamada, Naoko, Yamawaki, Takashi, Tanaka, Jun, Harada, Kazuki, Kashizaki, Fumihiro, Fukagawa, Masafumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies Antigens Antineoplastic Agents, Immunological - adverse effects C-Peptide - blood Carcinoma, Non-Small-Cell Lung - drug therapy Deoxyribonucleic acid Diabetes Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - chemically induced DNA Haplotypes Histocompatibility antigen HLA Humans Immune Checkpoint Inhibitors - adverse effects Insulin Letter to the Editor Letters to the Editor Lung Neoplasms - drug therapy Male Monoclonal antibodies Nivolumab - adverse effects Patients Peptides Thyroid gland Thyroiditis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.
ISSN:	2040-1116 2040-1124
DOI:	10.1111/jdi.13143